IntelliPharmaCeutics International Inc. (IPCI) EPS Estimated At $-0.07

June 20, 2018 - By Tina Thibodeau

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Logo

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.07 EPS on July, 10.They anticipate $0.01 EPS change or 16.67 % from last quarter’s $-0.06 EPS. After having $-0.09 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -22.22 % EPS growth. The stock decreased 2.20% or $0.0099 during the last trading session, reaching $0.4401. About 13,208 shares traded. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has declined 78.43% since June 20, 2017 and is downtrending. It has underperformed by 91.00% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering IntelliPharmaCeutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. IntelliPharmaCeutics Intl had 6 analyst reports since January 19, 2018 according to SRatingsIntel. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by H.C. Wainwright on Monday, February 12. The company was maintained on Monday, March 5 by H.C. Wainwright. On Friday, February 16 the stock rating was downgraded by Maxim Group to “Hold”. The rating was maintained by H.C. Wainwright on Tuesday, May 29 with “Buy”.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $18.88 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More news for IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were recently published by: Equitiesfocus.com, which released: “Reviewing IntelliPharmaCeutics Intl (NASDAQ:IPCI) & Cardiome Pharma (CRME)” on June 16, 2018. Stockhouse.com‘s article titled: “Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ” and published on June 08, 2018 is yet another important article.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.